Opportunities for future biological therapy in SLE

D. Wofsy; D. I. Daikh

doi:10.1016/S0950-3579(98)80034-4

Opportunities for future biological therapy in SLE

D. Wofsy, D. I. Daikh

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

The development of monoclonal antibodies and the emergence of recombinant DNA technology has made it possible to identify and selectively inhibit distinct cell subsets, surface molecules and secreted products that contribute to normal and pathological immune responses. These advances have helped to clarify the mechanisms that promote autoimmune diseases. As a result, it is now possible to contemplate rational strategies for the treatment of these diseases. Some of these strategies are designed to influence the cell surface interactions that determine whether potentially autoreactive T cells become activated or tolerant following antigen stimulation. Other strategies are designed to augment or inhibit distinct cytokines that regulate autoimmunity. All of these strategies have shown promise in animal models for systemic lupus erythematosus, and they may soon be translated into effective new therapies for people.

Original language	English (US)
Pages (from-to)	529-541
Number of pages	13
Journal	Bailliere's Clinical Rheumatology
Volume	12
Issue number	3
DOIs	https://doi.org/10.1016/S0950-3579(98)80034-4
State	Published - 1998
Externally published	Yes

Keywords

Interleukin 10
Interleukin 6
Murine lupus
T cell co-stimulation
Tumour necrosis factor-α

ASJC Scopus subject areas

Rheumatology

Access to Document

10.1016/S0950-3579(98)80034-4

Cite this

@article{0f7158a237bf49dbac885e5906a3d171,

title = "Opportunities for future biological therapy in SLE",

abstract = "The development of monoclonal antibodies and the emergence of recombinant DNA technology has made it possible to identify and selectively inhibit distinct cell subsets, surface molecules and secreted products that contribute to normal and pathological immune responses. These advances have helped to clarify the mechanisms that promote autoimmune diseases. As a result, it is now possible to contemplate rational strategies for the treatment of these diseases. Some of these strategies are designed to influence the cell surface interactions that determine whether potentially autoreactive T cells become activated or tolerant following antigen stimulation. Other strategies are designed to augment or inhibit distinct cytokines that regulate autoimmunity. All of these strategies have shown promise in animal models for systemic lupus erythematosus, and they may soon be translated into effective new therapies for people.",

keywords = "Interleukin 10, Interleukin 6, Murine lupus, T cell co-stimulation, Tumour necrosis factor-α",

author = "D. Wofsy and Daikh, {D. I.}",

year = "1998",

doi = "10.1016/S0950-3579(98)80034-4",

language = "English (US)",

volume = "12",

pages = "529--541",

journal = "Bailliere's Clinical Rheumatology",

issn = "0950-3579",

publisher = "Bailliere Tindall Ltd",

number = "3",

}

TY - JOUR

T1 - Opportunities for future biological therapy in SLE

AU - Wofsy, D.

AU - Daikh, D. I.

PY - 1998

Y1 - 1998

N2 - The development of monoclonal antibodies and the emergence of recombinant DNA technology has made it possible to identify and selectively inhibit distinct cell subsets, surface molecules and secreted products that contribute to normal and pathological immune responses. These advances have helped to clarify the mechanisms that promote autoimmune diseases. As a result, it is now possible to contemplate rational strategies for the treatment of these diseases. Some of these strategies are designed to influence the cell surface interactions that determine whether potentially autoreactive T cells become activated or tolerant following antigen stimulation. Other strategies are designed to augment or inhibit distinct cytokines that regulate autoimmunity. All of these strategies have shown promise in animal models for systemic lupus erythematosus, and they may soon be translated into effective new therapies for people.

AB - The development of monoclonal antibodies and the emergence of recombinant DNA technology has made it possible to identify and selectively inhibit distinct cell subsets, surface molecules and secreted products that contribute to normal and pathological immune responses. These advances have helped to clarify the mechanisms that promote autoimmune diseases. As a result, it is now possible to contemplate rational strategies for the treatment of these diseases. Some of these strategies are designed to influence the cell surface interactions that determine whether potentially autoreactive T cells become activated or tolerant following antigen stimulation. Other strategies are designed to augment or inhibit distinct cytokines that regulate autoimmunity. All of these strategies have shown promise in animal models for systemic lupus erythematosus, and they may soon be translated into effective new therapies for people.

KW - Interleukin 10

KW - Interleukin 6

KW - Murine lupus

KW - T cell co-stimulation

KW - Tumour necrosis factor-α

UR - http://www.scopus.com/inward/record.url?scp=0031737320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031737320&partnerID=8YFLogxK

U2 - 10.1016/S0950-3579(98)80034-4

DO - 10.1016/S0950-3579(98)80034-4

M3 - Article

C2 - 9890111

AN - SCOPUS:0031737320

SN - 0950-3579

VL - 12

SP - 529

EP - 541

JO - Bailliere's Clinical Rheumatology

JF - Bailliere's Clinical Rheumatology

IS - 3

ER -

Opportunities for future biological therapy in SLE

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this